Impact of a Triclosan-containing Toothpaste During the Progression of Experimental Peri-implant Mucositis

• ClinicalTrials.gov Identifier: NCT03145610
• Recruitment Status: Completed
• First Posted: May 9, 2017
• Last Update Posted: May 9, 2017
• Sponsor: Paulista University
• Information provided by (Responsible Party): Fernanda Vieira Ribeiro, Paulista University

Study Description

Brief Summary:

The aim of this study was to evaluate the influence of a triclosan-containing toothpaste in the profile of osteo-immunoinflammatory mediators in the peri-implant crevicular fluid (PICF) and in the clinical parameters during the progression of experimental peri-implant mucositis.

Condition or disease	Intervention/treatment	Phase
Biological Markers; Dental Implants; Cytokines; Triclosan; Toothpastes; Peri-Implantitis; Microbiology	Other: Placebo toothpaste; Other: triclosan/copolymer/fluoride toothpaste	Not Applicable

Detailed Description:

Study design This investigation was designed as double-blind, randomized, crossover study to evaluate the influence of a triclosan-containing toothpaste in the profile of osteo-immunoinflammatory mediators in the PICF and in the clinical parameters during the progression of experimental peri-implant mucositis. This study was approved by the ethics committee of Paulista University (Protocol 97.117).

Population screening Patient recruitment started in June 2013 and was completed by the end of May 2014. The clinical procedures and evaluations were carried out between August 2013 and June 2014. Data entry and statistical analyses were performed in January 2015. All the patients in the study were recruited from the patients referred to Paulista University.

All eligible individuals were thoroughly informed of the nature, potential risks and benefits of their participation in the study, and they each signed an informed consent document.

Experimental groups During an experimental 3-week period of undisturbed plaque accumulation in the implants, patients were randomly assigned to two groups, according to chemical plaque control (three times per day): Triclosan (n=11): triclosan/copolymer/fluoride toothpaste or Placebo (n=11): fluoride toothpaste. Undisturbed plaque accumulation was achieved only in the nearby of dental implants by using an individual silicone tray involving the implant and adjacent teeth covering 2-3mm of peri-implant mucosa. The same silicone tray was filled by the respective toothpaste, according to the experimental group, during this period. Following 3 weeks, a professional prophylaxis was performed and a wash-out period of 30 days was established. Then, a second experimental 3-week period of undisturbed plaque accumulation in the implants was established and the experimental groups were exchanged. After that, a new professional prophylaxis was performed. All evaluations (clinical and immunoenzimatic assays) were performed at baseline, 3, 7, 14 and 21 days of each period of experimental mucositis induction.

The number of patients included in the present study was based on previous crossover investigations that found differences in the clinical parameters and crevicular fluid levels of osteo-immunoinflammatory markers in different clinical status.

Clinical examination The same examiner, who was blinded to the groups, performed all measurements of clinical assessment. To perform the intra-examiner calibration, 15 non-study individuals presenting dental implants were selected. The examiner measured the PD of all patients twice within 24 hours. The examiner was judged to be reproducible after fulfilling the pre-determined success criteria (the percentage of agreement within ± 1 mm between repeated measurements had to be at least 90%). The intra-class correlation was calculated as 92% reproducibility.

An individual stent was prepared to standardize the location of periodontal probe (North Carolina - Hu-Friedy, Chicago, IL, USA) to evaluate the following parameters at four sites of the experimental dental implants at baseline, 3, 7, 14, 21 days follow-ups: 1) plaque index (PI/%): scored using a dichotomous plaque index along the mucosal margin around implants, 2) bleeding index (BI/%): scored using dichotomous index of mucosal marginal bleeding around implants, 3) Position of the peri-implant margin (PPM/mm), which was the distance from the stent to the peri-implant margin; 4) Relative clinical attachment level (RCAL/mm), which was the distance from the stent to the bottom of the peri-implant pocket; and 5) Peri-implant probing depth (PD/mm), calculated by deducting PPM from RCAL. The full mouth plaque scores (FMPS) and bleeding scores (FMBS) were calculated before the beginning of each period of experimental mucositis induction.

Osteo-immunoinflammatory profile assessment Peri-implant crevicular fluid was collected from dental implant sites by the same examiner. The area was isolated, dried and fluid was collected at two sites of the experimental dental implants (vestibular and lingual) by placing filter paper strips (Periopaper, Oraflow, Plainview, NY, USA) into the sulcus until the clinician perceived a slight resistance, and then leaving in place for 15 s. The fluid volume was measured with a calibrated device (Periotron 8000, Oraflow, Plainview, NY, USA). The strips were placed into sterile tubes containing 400 μL of phosphate-buffered saline (PBS) with 0.05% Tween-20. Peri-implant crevicular fluid samples were immediately stored at -20 °C.

Levels of interferon (INF), interleukin (IL)-4, IL-17, IL-1β, IL-10, IL-6, IL-23, tumor necrosis factor (TNF)-α (Human Th17 HTH17MAG-14K, Millipore Corporation, Billerica, MA, USA), osteoprotegerin (OPG), osteocalcin (OC), osteopontin (OPN) (Human Bone HBNMAG-51K, Millipore Corporation, Billerica, MA, USA), matrix metalloproteinase (MMP)-2, MMP-9 (Human MMP Panel 2 HMMP2MAG-55K, Millipore Corporation, Billerica, MA, USA), transforming growth factor (TGF)-β (Multi-species TGFβ TGFBMAG-64K, Millipore Corporation, Billerica, MA, USA) and crosslinked telopeptide of type I collagen (ICTP) (Uscn Life Science Inc. Wuhan, Hubei, PRC) in the peri-implant fluid were determined using commercially available kits. Assays were carried out according to the manufacturer's recommendations using the MAGpix™ instrument (MiraiBio, Alameda, CA, USA). The samples were individually analyzed, and concentrations were estimated from the standard curve using a five-parameter polynomial equation using Xponent® software (Millipore, Corporation, Billerica, MA, USA). The mean concentration of each mediator was calculated using the individual as a statistical unit and expressed as pg/ml.

Data analysis All analyses were performed using SAS program release 9.1 (Cary, NC, USA). Data were firstly examined for normality using the Kolmogorov-Smirnov test, and the data that achieved normality were analysed using parametric methods. The percentages of experimental sites with visible plaque accumulation, BI and the PD means were computed for each implant selected for peri-implant fluid sampling. Subsequently, clinical parameters and the local levels of osteo-immunoinflammatory mediators were averaged into Placebo and Triclosan groups. The differences in FMPS and FMBS - measured before the beginning of each period of experimental mucositis induction.- between both groups were compared using the Wilcoxon test. For the other clinical parameters (PI, BI, PPM, RCAL and PD), ANOVA/Tukey test was used to detect differences between groups and periods. Concentrations of osteo-immunoinflammatory markers between groups and among follow-ups were compared using the Wilcoxon and Friedman test, respectively. An experimental level of significance was determined at 5% for all statistical analyses.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 22 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: This investigation was designed as double-blind, randomized, crossover study
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Impact of a Triclosan-containing Toothpaste During the Progression of Experimental Peri-implant Mucositis: Clinical Parameters and Local Pattern of Osteo-immunoinflammatory Mediators in Peri-implant Fluid
• Actual Study Start Date: June 1, 2013
• Actual Primary Completion Date: May 30, 2014
• Actual Study Completion Date: January 14, 2015

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo toothpaste; Fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.	Other: Placebo toothpaste; During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
Experimental: triclosan/copolymer/fluoride toothpaste; triclosan/copolymer/fluoride toothpaste will be used by filling the individual silicone stent allowing it to come into contact with the implant area for 2 min.	Other: triclosan/copolymer/fluoride toothpaste; During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.

Outcome Measures

Primary Outcome Measures :

1. bleeding index [ Time Frame: 21 days ]
   scored using dichotomous index of mucosal marginal bleeding around implants,

Secondary Outcome Measures :

1. plaque index [ Time Frame: 21 days ]
   scored using a dichotomous plaque index along the mucosal margin around implants
2. Position of the peri-implant margin [ Time Frame: 21 days ]
   distance from the stent to the bottom of the peri-implant pocket;
3. Peri-implant probing depth [ Time Frame: 21 days ]
   calculated by deducting PPM from RCAL
4. Relative clinical attachment level [ Time Frame: 21 days ]
   which was the distance from the stent to the bottom of the peri-implant pocket;
5. Osteo-immunoinflammatory mediators [ Time Frame: 21 days ]
   Levels of interferon (INF), interleukin (IL)-4, IL-17, IL-1β, IL-10, IL-6, IL-23, tumor necrosis factor (TNF)-α (Human Th17 HTH17MAG-14K, Millipore Corporation, Billerica, MA, USA), osteoprotegerin (OPG), osteocalcin (OC), osteopontin (OPN) (Human Bone HBNMAG-51K, Millipore Corporation, Billerica, MA, USA), matrix metalloproteinase (MMP)-2, MMP-9 (Human MMP Panel 2 HMMP2MAG-55K, Millipore Corporation, Billerica, MA, USA), transforming growth factor (TGF)-β (Multi-species TGFβ TGFBMAG-64K, Millipore Corporation, Billerica, MA, USA) and crosslinked telopeptide of type I collagen (ICTP) (Uscn Life Science Inc. Wuhan, Hubei, PRC) in the peri-implant fluid were determined using commercially available kits.

Eligibility Criteria

• Ages Eligible for Study: 30 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• 30 years old or more
• present at least a 2-stage unitary screwed implant-supported single-unit crown in the molar or pre-molar region
• implant connection should be external hexagonal and the implants should be in function at least 12 months with width of keratinized tissue > 2mm around implants
• The peri-implant tissue should be healthy [probing depth (PD) <4mm with no bleeding on probing (BoP) and no evidence of radiographic bone loss beyond bone remodeling (AAP 2013).
• Patients should be periodontally healthy and present full mouth plaque scores (FMPS, Ainamo & Bay 1975) and bleeding score (FMBS, Muhlemann & Son 1971) < 20%.

Exclusion Criteria:

• pregnancy
• lactation
• smokers
• systemic conditions r that could affect the progression of peri-implant diseases and bone metabolism (e.g., immunologic disorders), use of long-term administration of anti-inflammatory and immunosuppressive medications
• antibiotic therapies in the previous 6 months
• individuals that required bone grafts before or alongside the implant surgery
• history of previous regenerative procedures in the area treated with implant therapy.

Contacts and Locations

No Contacts or Locations Provided

More Information

• Responsible Party: Fernanda Vieira Ribeiro, Professor, Paulista University
• ClinicalTrials.gov Identifier: NCT03145610
• Other Study ID Numbers: Triclosan Mucositis
• First Posted: May 9, 2017
• Last Update Posted: May 9, 2017
• Last Verified: May 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Mucositis; Peri-Implantitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Mouth Diseases; Stomatognathic Diseases; Periodontal Diseases; Triclosan; Fluorides; Cariostatic Agents; Protective Agents; Physiological Effects of Drugs; Anti-Infective Agents, Local; Anti-Infective Agents; Fatty Acid Synthesis Inhibitors; Hypolipidemic Agents; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Lipid Regulating Agents